Enveric Biosciences (ENVB) Change in Accured Expenses (2011 - 2026)

Enveric Biosciences has reported Change in Accured Expenses for 16 years, with the latest figure at -$417390.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 38.54% year-over-year to -$417390.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$529973.0 (up 60.4% YoY) and the FY2025 annual result came in at -$413864.0, up 50.41% from the prior year.
• Change in Accured Expenses slipped to -$417390.0 in Q1 2026 per ENVB's latest filing, from -$117882.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $653712.0 in Q1 2023 and troughed at -$1.7 million in Q2 2024.
• A 5-year average of -$88590.9 and a median of -$111315.0 in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses jumped 10757.2% in 2023, then plunged 1392.22% in 2024.
• Over 5 years, Change in Accured Expenses stood at $370361.0 in 2022, then tumbled by 244.06% to -$533536.0 in 2023, then soared by 186.64% to $462277.0 in 2024, then tumbled by 125.5% to -$117882.0 in 2025, then sank by 254.07% to -$417390.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$417390.0, -$117882.0, and -$284682.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.